Beam president trades 35,000 shares in Form 4

Beam Therapeutics President Giuseppe Ciaramella reported insider transactions involving 35,000 shares on Common Stock.

Accepted by SEC EDGAR 02/26/2026 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Beam Therapeutics President Giuseppe Ciaramella reported insider transactions involving 35,000 shares on Common Stock. He exercised a stock option for 35,000 shares at $17.00 per share, converting a derivative award into directly held Common Stock.

On the same date, he then sold 35,000 shares of Common Stock at a weighted average price of $32.0012 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2025. Following these transactions, he directly owned 190,216 shares of Common Stock and 397,313 shares underlying stock options.

Insider Trade Summary

Exercise and Sale: 35,000 shares ($525K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Ciaramella Giuseppe

Role President

Sold 35,000 shs ($1.12M)

Approx. gross sale proceeds $1.12M

Approx. exercise cost $595K

Approx. pre-tax spread $525K

Share of Position Sold 15.5%

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	35,000	$0.00	$0.00
Exercise	Common Stock	35,000	$17.00	$595K
Sale	Common Stock	35,000	$32.0012	$1.12M

Holdings After Transaction: Stock Option (Right to Buy) — 397,313 contracts (Direct); Common Stock — 190,216 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 432,313 to 397,313 contracts (Direct); Common Stock, 190,216 to 190,216 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (3)

1. F1. The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.04, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The option vests as to 25% on the first anniversary of the of the vesting commencement date, February 5, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ciaramella Giuseppe

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		M		35,000	A	$17	225,216	D
Common Stock	02/24/2026		S(1)		35,000	D	$32.0012(2)	190,216	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17	02/24/2026		M			35,000	(3)	02/05/2030	Common Stock	35,000	$0	397,313	D

Explanation of Responses:

1. The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.04, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The option vests as to 25% on the first anniversary of the of the vesting commencement date, February 5, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.

	By: /s/ Christine Bellon, Attorney-in-fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.